medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2015, Number 3

<< Back Next >>

VacciMonitor 2015; 24 (3)

Antigenic and molecular characterization of influenza A (H3N2) virus strains circulating in Cuba and their relation with vaccine strains (1995-98)

Oropesa-Fernández S, Goyenechea-Hernández A, Savón-Valdés C, Acosta-Herrera B, Piñón-Ramos A, Gonzalez-Muñoz G, Valdés-Ramírez O, Arencibia-García A, Muné-Jimenez M, Espinosa-Hernández B, González-Báez G

Language: Spanish
References: 20
Page: 105-112
PDF size: 718.17 Kb.


ABSTRACT

The continuous antigenic changes in the influenza viruses occurring primarily on the envelope glycoproteins (hemagglutinin and neuraminidase) are due to specific mutations and to those promoted by the positive selection of the immune system originating the yearly epidemics and the rearrangements of genomic segments, cause of the feared pandemics. The attempts to control the influenza by means of vaccination have so far a limited success and they are obstructed by these changes. The acute respiratory infections are the first cause of medical assistance among the infectious diseases in Cuba, a subtropical country and the fourth cause of death associated with pneumonia. The surveillance for the influenza in this country is monitored by the National Center of Influenza from “Pedro Kourí” Tropical Medicine Institute. The present paper has the objective to characterize 21 strains of influenza isolated from 1995 to 1998 and to know the antigenic and genomic similarity with those of the international circulation included in anti-flu of the same period. The antigenic and genomic characterization was carried out by means of the inhibition techniques of hemagglutination, immunoperoxidase, and a reverse system of transcription-polymerase chain reaction, respectively. Using these three techniques 100% of the isolations were of the type A and the subtype H3N2. It allowed to classify them as similar to the circulating strains of international circulation recommended in the composition of the flu vaccine corresponding to those season.


REFERENCES

  1. Taurenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006;12(1):15-22.

  2. Smith DJ. Applications of bioinformatics and computational biology to influenza surveillance and vaccine strain selection. Vaccine 2003;21:1758-61.

  3. Anuario estadístico de Salud, 2012. Dirección Nacional de Estadística de Salud. La Habana: Ministerio de Salud Pública de la República de Cuba; 2013.

  4. Fouchier R, Munster V, Wallensten A, Bestebroer T, Hersfst S, Smith D. Characterization of a Novel Influenza Virus hemagglutinin Subtype (H16) obtained from Black-Headed Gulls. Journal of Virology 2005;79(5):2814-22.

  5. Strengell M, Ikonen N, Ziegler T, Julkunen I. Minor changes in the hemagglutinin of influenza A (H1N1) 2009 virus alter its antigenic properties. Plos One 2011;6:e25848. Disponible en http://www.ncbi.nlm.nih.gov/pubmed/22022458

  6. Palmer D, Dowdle W, Coleman M, Schild G. Advanced laboratory techniques for influenza diagnosis. Immunology Series No 6. Part. 2: Procedural Guide, Atlanta: US Department of Health Education and Public Health Service; 1975. p:25-62.

  7. Ziegler T, Hall H, Sánchez Fauquier A, Gamble WC, Cox N. Type and subtype specific detection of influenza virus in clinical specimens by rapid culture assay. J Clin Microbiol 1995;33:318-21.

  8. Cane PA and Pringle CR. Molecular epidemiology of respiratory syncytial virus: rapid identification of subgroup A lineages. J Virol Methods 1992;40:297-306.

  9. Moattari A, Ashrafi H, Kadivar MR, Kheiri MT, Shahidi M, Arabpour M et al. Antigenic variations of human influenza virus in Shiraz, Iran. Indian Journal of Medical Microbiology 2010;28(2):114-9.

  10. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999;17 Suppl 1: S3-10.

  11. Ansart S, Pelat C, Boelle PY, Carrat F, Flahault A, Valleron AJ. Mortality burden of the 1918-1919 influenza pandemic in Europe. Influenza Others Respir Viruses 2009;3(3):99-106.

  12. Smith D. Culture collections over the world. Int Microbiol 2003;6:95-100.

  13. WHO. WER. Influenza (Flu). Influenza Summary 1995;70(8):53-60. Disponible en: http://www.who.int.wer

  14. WHO. National Advisory Committee on Immunization. Statement on influenza vaccination for the 1996-97 season. CCDR 1996;22:89-97. Disponible en: http://www.who.int.wer

  15. WHO. WER. Influenza (Flu). Influenza Summary 1996;71(8):57-64. Disponible en: http://www.who.int.wer

  16. WHO.WER. Influenza (Flu). Influenza Summary 1997;72(7):41-7. Disponible en: http://www.who.int.wer

  17. WHO. WER. Influenza (Flu). Influenza Summary 1998;73(7):41-8. Disponible en: http://www.who.int.wer

  18. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010;134:235-43.

  19. He F, Du Q, Ho Y, Kwang J. Immunohistochemical detection of Influenza virus infection in formalin-fixed tissues with anti-H5 monoclonal antibody recognizing FFWTILKP. J Virol Methods 2009;155:25-33.

  20. Ruiz-Carrascoso G, Casas I, Pozo F, Pérez-Gonzalez C, Reina J, Perez-Breña P, et al. Development and implementation of influenza A virus subtyping and detection of genotypic resistance to neuraminidase inhibitors. J Med Virol 2010;82:843-53.




2020     |     www.medigraphic.com